High-Yield Mesenchymal Stem/Stromal Cell (MSC) Expansion At The Forefront Of Cell Therapy Advancement

MSC biology is no longer the open question. The harder problem is producing enough consistent, high-quality cells as indications multiply, doses grow, and products shift from autologous to allogeneic. In this interview, Hilary Sherman, Senior Applications Scientist at Corning, discusses how scalability, reproducibility, and efficacy shape high-yield expansion. The conversation looks at why adding flasks stops working, how vessel formats compare on growth area and incubator footprint, and what closed-system workflows mean for contamination risk and operator-dependent variability. It also considers the overlooked influence of media on yield, and how changes in surface chemistry, formulation, and handling can cause process drift between bench and manufacturing.

Access the full article to see how Sherman connects these choices into a single scale-up strategy.